Exercise training in childhood cancer survivors with subclinical cardiomyopathy who were treated with anthracyclines

Pediatric Blood and Cancer

Volumn 61, Issue 5, 2014, Pages 942-945

  Smith, Webb A ^a   Ness, Kirsten K ^a   Joshi, Vijaya ^b   Hudson, Melissa M ^a   Robison, Leslie L ^a   Green, Daniel M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Anthracyclines; Cardiomyopathy; Childhood cancer survivor; Exercise training; Strength training

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOPULMONARY FUNCTION; CHILDHOOD CANCER; CLINICAL ARTICLE; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FEMALE; HEART EJECTION FRACTION; HUMAN; KNEE AMPUTATION; LUNG GAS EXCHANGE; MALE; ONSET AGE; OXYGEN CONSUMPTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESISTANCE TRAINING; STRENGTH; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84895730861     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24850     Document Type: Article

References (20)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
2. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355:1572-1582.
3. Oeffinger KC, Buchanan GR, Eshelman DA, et al. Cardiovascular risk factors in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2001; 23:424-430.
4. Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: A multi-institutional collaborative project. Med Pediatr Oncol 2002; 38:229-239.
5. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience. J Clin Oncol 1997; 15:1544-1552.
6. Steinherz LJ, Steinherz PG, Tan CTC, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266:1672-1677.
7. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23:2629-2636.
8. Kremer LCM, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-term follow-up study. J Clin Oncol 2001; 19:191-196.
9. Hudson MM, Rai SN, Nunez C, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 2007; 25:3635-3643.
10. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22:4979-4990.
11. Hambrecht R, Gielen S, Linke A, et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: A randomized trial. JAMA 2000; 283:3095-3101.
12. Pu CT, Johnson MT, Forman DE, et al. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. J Appl Physiol 2001; 90:2341-2350.
13. Hudson MM, Ness KK, Nolan VG, et al. Prospective medical assessment of adults surviving childhood cancer: Study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort study. Pediatr Blood Cancer 2011; 56:825-836.
14. Fletcher GF, Balady G, Blair SN, et al. Statement on exercise: Benefits and recommendations for physical activity programs for all Americans: A statement for health professionals by the committee on exercise and cardiac rehabilitation of the council on clinical cardiology. American Heart Association. Circulation 1996; 94:857-862.
15. Armstrong L, Balady GJ, Berry MJ, Davis SE, Davy BM, Davy KP, et al. Other Clinical Conditions Influencing Exercise Prescription. In: Whaley MH, Brubaker PH, Otto RM, editors. ACSM's Guidelines for Exercise Testing & Prescription. 7th ed. Baltimore: Lippincott, Williams & Wilkins, Inc.; 2006. pp. 205-236.
16. Pollock ML, Franklin BA, Balady GJ, et al. Resistance exercise in individuals with and without cardiovascular disease: Benefits, rationale, safety, and prescription an advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology. American Heart Association. Circulation 2000; 101:828-833.
17. Belardinelli R, Georgiou D, Cianci G, et al. Exercise training improves left ventricular diastolic filling in patients with dilated cardiomyopathy: Clinical and prognostic implications. Circulation 1995; 91:2775-2784.
18. Belardinelli R, Georgiou D, Cianci G, et al. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: Effects on functional capacity, quality of life, and clinical outcome. Circulation 1999; 99:1173-1182.
19. Magnusson G, Kaijser L, Rong H, et al. Exercise capacity in heart failure patients: Relative importance of heart and skeletal muscle. Clin Physiol 1996; 16:183-195.
20. Schulze PC, Gielen S, Schuler G, et al. Chronic heart failure and skeletal muscle catabolism: Effects of exercise training. Int J Cardiol 2002; 85:141-149.